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Introduction
Neurological and neurosurgical conditions are
encountered occasionally during pregnancy, but serious
neurological complications of pregnancy are rare.
Nevertheless, the range of neurological conditions
affecting women of reproductive age is extremely
broad.1,2 In this article, we present data on the incidence
of various neurological conditions in a local obstetric
population; the data were obtained by a retrospective
review of all deliveries in the Tsan Yuk Hospital and
the Queen Mary Hospital from 1 January 1985 through
31 December 1994. In addition, important concepts
and recent advances in the treatment of these conditions
are discussed.
Subjects and methods
Patients were identified from the obstetric audit
database of the Department of Obstetrics and
Gynaecology, The University of Hong Kong, over the
10-year period, and the original records and/or micro-
film were retrieved to confirm diagnoses and to ex-
tract information. Only conditions requiring medication
or active intervention during pregnancy were included,
whereas a past history of a neurological diagnosis
per se and conditions not requiring treatment were
excluded from further analysis. Statistical comparisons
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were made using the Chi squared test with a probabil-
ity level of 0.05 or below used to indicate significance.
Results
The total number of deliveries during the study period
was 49 368. One hundred and sixty-one patients had
various neurological diagnoses, giving an incidence
of 326 per 100 000 pregnancies. Table 1 summarises
the various conditions and their incidence.
Epilepsy was the most common neurological con-
dition encountered, affecting 102 patients (Table 1).
These patients were maintained on antiepileptic medi-
cations throughout their pregnancies. Patients who
had a past history of seizure or epilepsy and were
Table 1. Incidence of various neurological condit-
ions found in pregnant women attending the Tsan
Yuk and Queen Mary hospitals from 1 January
1985 through 31 December 1994
Condition No. Incidence per 100 000
pregnancies
Epilepsy 102 207
Eclampsia 19 39
Facial nerve palsy 12 24
Pituitary tumour 10 20
Cerebrovascular 7 14
 disorders
Myasthenia gravis 5 10
Multiple sclerosis 4 8
Non-pituitary 2 4
 intracranial tumour
Total 161 326
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not taking any medication were excluded. The anti-
epileptic medications included phenobarbital, carba-
mazepine, sodium valproate, and phenytoin. It is
impossible to interpret the quality of seizure control
during pregnancy, because the frequency of seizures
and drug compliance were not recorded systematically
before pregnancy and because this group could repre-
sent a biased sample of epileptic patients who decided
to become pregnant after achieving good control of
their seizures. About 80% of these patients were seizure-
free during pregnancy, and the rest had infrequent
minor attacks in the antepartum period. One patient,
who was not taking any antiepileptic medication
during pregnancy, and two other patients with poor
drug compliance had a seizure on the second day post-
partum; antiepileptic medications were re-started
and no further seizures occurred. Maternal and foetal
complications occurred in 28% of these patients, but
there was no significant difference between the
incidences of various complications compared with
those for non-epileptic women of the same cohort
(Table 2). Congenital malformations were documented
in 6.86% of deliveries by epileptic patients; there
was no preponderance for cleft lip and/or palate
(Table 2).
Eclampsia was the second most common neuro-
logical condition, affecting 19 patients (Table 1).
During the study period, 2969 patients were diagnosed
with gestational hypertension, and eclampsia de-
veloped in 0.64% of these patients. In 11 eclamptic
patients, seizures developed before delivery, and the
remainder had eclamptic seizures within 24 hours of
delivery. Eclampsia was associated with one perinatal
and one neonatal death. Twelve patients had idiopathic
facial nerve palsy. The nerve palsy occurred during
the third trimester in five patients and in the early
post-partum period in another five. There was no pre-
dilection for any particular side of the face; bilateral
facial nerve palsy was not reported. All 10 patients
with pituitary tumours had prolactinomas. Bromo-
criptine was given to these patients because two had a
macroadenoma. The remainder were re-started on
bromocriptine because of progressive symptoms such
as headache, recurrent vomiting, and deteriorating
visual fields. One patient had progressive enlargement
of her tumour during the third trimester despite medi-
cal therapy, and required a simultaneous transphenoidal
resection of tumour and caesarean section near term.
None of the babies born to these mothers had congeni-
tal anomalies.
Table 3 shows the history and results for seven
patients who had cerebrovascular disorders while
pregnant. The first two patients received special
attention during pregnancy and intensive monitoring
during delivery because of a prior history of sub-
arachnoid haemorrhage; they both had a good outcome.
The remaining five patients had an intracranial haem-
orrhage during pregnancy and had variable outcomes.
Causes of these intracranial haemorrhages included
a vascular malformation, an aneurysm, or the use of
anticoagulant medication.
Five patients with myasthenia gravis were pregnant
in this series. All were carefully monitored through-
out their pregnancies with continuation of pyrido-
stigmine bromide, and their pregnancies, labour, and
Table 2. Maternal and foetal complications found in epileptic and non-epileptic patients
Maternal and foetal complications Epileptic patients, Non-epileptic patients, P value
n=102 n=49 266
No. (%) No. (%)
Antepartum haemorrhage 4 (3.92) 1566 (3.18) ns
Gestational hypertension 5 (4.90) 2964 (6.02) ns
Preterm delivery (<37 weeks)  12 (11.76)  6638 (13.47) ns
Congenital malformations:
     - cardiovascular 3 (2.94) 430 (0.87)
     - cleft lip/palate 2 (1.96) 212 (0.43)
     - chromosomal abnormalities 1 (0.98) 87 (0.18)
     - multiple abnormalities 1 (0.98) 73 (0.15)
     - other* 0 759 (1.88)†
     Total 7 (6.86) 1561 (3.17) ns
Neonatal death 1 (0.98) 252 (0.51) ns
ns    not significant
*More than one other congenital malformation, not classifiable as ‘multiple abnormalities’
†An additional 169 (0.34%) patients had more than one of the listed congenital malformations
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deliveries were uneventful. None of the babies had
neonatal myasthenia gravis. Three patients who were
known to have multiple sclerosis became pregnant, and
a fourth patient developed right-sided optic neuritis
as the presenting symptom of multiple sclerosis at 30
weeks’ gestation. Table 4 summarises the salient fea-
tures of these four patients, including the presenting
symptoms, symptoms in the antenatal and post-
partum periods, and outcomes of the neonates. Two of
the three patients who were known to have multiple
sclerosis experienced a relapse during the third trimes-
ter, but their symptoms improved in the post-partum
period. Two patients with non-pituitary intracranial
tumours were seen. One patient, who presented with
sudden collapse, had a craniotomy and resection of
her left frontal glioma at 29 weeks’ gestation. Subse-
quently, she had an uneventful lower segment caesarean
section at 34 weeks’ gestation. Another patient, who
had a left optic nerve meningioma and visual loss,
had a tumour resection after the labour and delivery
had been completed.
Discussion
The data reflect the experience in a major district ob-
stetric hospital (the Tsan Yuk Hospital) and a related
tertiary referral unit for high-risk pregnancies (the
Queen Mary Hospital). Retrospective analyses of
Table 3. Cerebrovascular disorders complicating pregnancy
Patient Condition Treatment Outcome
1 Past history of SAH* due to an Antiepileptic medications; Good
arteriovenous malformation; elective caesarean section at term
post-SAH epilepsy
2 Past history of SAH due to a Regular neurological surveillance; Good
frontal parasagittal arteriovenous cranial MRI†; elective caesarean
malformation section at term
3 IVH‡ due to corpus callosal Right parietal craniotomy; external Good; minimal residual
arteriovenous malformation ventricular drainage; right frontal neurological deficits
at 15 weeks’ gestation ventriculostomy at 15 weeks’
gestation; antiepileptic medication;
elective caesarean section at term
4 SAH at 24 weeks’ gestation Prolonged mechanical ventilation Preterm labour at 30
weeks’ gestation with
stillbirth; vegetative state
postpartum
5 SAH due to a cerebral aneurysm Craniotomy with clipping of the Good; minimal residual
at 18 weeks’ gestation aneurysm at 19 weeks’ gestation; deficit
elective caesarean section at 36
weeks for breech and previous
cerebrovascular haemorrhage
6 Left occipito-parietal haemorrhage Conservative; temporary cessation Complete recovery
after caesarean section under of anticoagulation
general anaesthesia; mitral valvular
replacement with heparin in the
peripartum period
7 Chronic rheumatic heart disease Craniotomy and drainage of subdural Prolonged vegetative state
with mitral valvular replacement; haematoma on artificial ventilation;
subcutaneous heparin in first succumbed at 18 weeks’
trimester; spontaneous subdural gestation with pregnancy
haematoma at 11 weeks’ gestation in situ
*SAH    subarachnoid haemorrhage
†MRI    magnetic resonance imaging
‡IVH    intraventricular haemorrhage
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the data and the selection bias of the obstetric cases
seen at these two hospitals did not permit an accurate
determination of the local incidence of various neuro-
logical conditions at pregnancy.
Epilepsy
Epilepsy is a common neurological disorder charac-
terised by a tendency to develop recurrent seizures.3
Epidemiological studies have suggested that about
7% of epileptic females become pregnant during
their lifetime and that approximately 0.5% of all
pregnancies are complicated by epilepsy4; 0.2% of
patients had epilepsy in this report. Our figure is
low because patients who had a previous history of
epilepsy but were not on any antiepileptic medica-
tion were not included in our analysis. As patients
may not volunteer a remote history of epilepsy, a
prospective study is needed to provide an accurate
figure. Knight and Rhind report that the control of
epilepsy during pregnancy becomes worse in 45%
of patients, is unchanged in 50%, and improves in
5%.5 Four recent studies show that a majority (60%
to 83%) of pregnant epileptic patients experience
no significant change in seizure frequency, but
changes in seizure frequency are unpredictable in
individual patients.6 Poor seizure control prior to
pregnancy is associated with an increased seizure
frequency during pregnancy.5,6 The pathophysiologi-
cal factors responsible for increased seizure fre-
quency during pregnancy include hormonal changes,
pharmacokinetic alterations, use of folate supple-
mentation, metabolic changes, sleep deprivation,
non-compliance with antiepileptic medications, and
stress and anxiety.
Oestrogens have been shown to be epileptogenic
in both animal and human studies while gona-
dotropins reduce the seizure threshold in animals.
Conversely, progesterone has antiepileptic effects
in both animals and humans.6 Thus, elevated in
plasma oestrogen, a high plasma oestrogen to pro-
gesterone ratio, and increased serum chorionic go-
nadotropin levels may account for the increased
seizure frequency seen in the first trimester.7 In ad-
dition, the natural alterations in the ratio between
oestrogen and progesterone that occur during the
menstrual cycle are responsible for catamenial epi-
lepsy i.e. affected epileptic women have increased
seizure frequency prior to and during menstruation
and at ovulation, but have infrequent attacks in the
mid-luteal phase.8
Pharmacokinetic changes arise during pregnancy
that result in a steady decline in both the total and
free serum levels of all anticonvulsants, except for
free valproic acid which may increase.9 This decline
in serum levels is caused by many factors, including a
larger volume for drug distribution, reduced plasma
protein binding, decreased albumin concentration,
increased renal clearance, hepatic microsomal enzyme
induction, and impaired intestinal absorption. The
total, and preferably, the free serum levels of anti-
convulsants should thus be monitored throughout
pregnancy and the puerperium.
Table 4. Multiple sclerosis complicating pregnancy
Patient Presenting Symptoms in Symptoms in Neonatal
symptom antenatal period post-partum period outcome
1 Bilateral lower limb Bilateral blurring of vision Visual symptoms improved Good
weakness in third trimester
2 Bilateral lower limb Bilateral optic neuritis and Visual and urinary symptoms Good
weakness urinary retention in third improved with increased
trimester steroid dosage
3 Bilateral lower limb Stationary during pregnancy, Stationary Prelabour ROM*
weakness otherwise ambulatory at 34 weeks’
gestation; LSCS†
for foetal
distress;
mild IUGR‡
4 Right optic neuritis at Condition improved with Neuropathic bladder requiring Good
30 weeks’ gestation steroids prolonged catheterisation
*ROM    rupture of membranes
†LSCS    lower segment caesarean section
‡IUGR    intrauterine growth retardation
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Folate supplementation before and during preg-
nancy is becoming a routine practice to reduce the
risk of major congenital malformations. In theory,
folate supplementation may lower the serum pheno-
barbital and phenytoin levels, but supportive evidence
for this is lacking.6 Pregnancy is associated with weight
gain, water and sodium retention, hypomagnesaemia,
and other metabolic changes. The contribution of
these changes to increased seizure frequency during
pregnancy remains unresolved.
Sleep deprivation reduces the seizure threshold
and is occasionally used before electroencephalo-
graphic recording to provoke epileptiform discharges.6
Insomnia from physical and psychological causes is
common during pregnancy. Drug compliance is a
common problem of all chronic diseases. Schmidt
and colleagues report that sleep deprivation or non-
compliance was temporally associated with seizures
in 34 of 50 women during their pregnancies and in
five of six women in the puerperium.10 Well-intentioned
non-compliance is common, because of the fear of
teratogenicity.11 Stress and anxiety also increase the
risk of seizures and may contribute to poor seizure
control during pregnancy.
Epilepsy is associated with mental retardation,
lower socioeconomic status, unemployment, lower
marital rates, and reduced fertility.6 Oral contracep-
tives interact with antiepileptic medication so that rates
of contraceptive failure are higher, and a larger dose
of antiepileptic medication may be required. Offspring
of epileptic mothers have an approximately three times
greater risk of developing seizures, whereas offspring
of epileptic fathers have no greater risk.12 Although
genetic counselling is advisable, the genetic transmis-
sion of epilepsy should not be overstated. Uncontrolled
seizures during pregnancy are dangerous to both the
mother and foetus. Tonic-clonic seizures can cause
physical injury and abruptio placentae in the mother
and hypoxia, acidosis, intracranial haemorrhage, and
death in the foetus.6 Thus, a balance should be achieved
between maternal seizure control and potential foetal
teratogenicity. There seems to be a residual effect
from antiepileptic medication, as studies have revealed
a higher risk of teratogenicity in epileptic women
taking antiepileptic medication when compared with
untreated epileptic pregnant women.13 The highest
incidence of congenital abnormalities has been found
in babies exposed to multiple antiepileptic medi-
cations in utero.4,14 In addition, babies of epileptic
fathers are at risk of congenital malformations.13,15 The
relative teratogenicity of many commonly prescribed
antiepileptic medications has not been resolved with
certainty, and no antiepileptic medication is free of
this side effect.6,16 Although some authors report a low
teratogenic risk for phenytoin,17 the foetal hydantoin
syndrome is well recognised. Trimethadione should
be avoided in pregnancy and in women of reproduc-
tive age, as the incidence of spontaneous abortion
and congenital malformations is as high as 37%.18 A
prospective study reports that carbamazepine is asso-
ciated with developmental delay, craniofacial defects,
and fingernail hypoplasia in 20% of exposed children.19
Spina bifida was found in 1.5% of foetuses exposed
to sodium valproate during the first trimester;20 and
this drug should be avoided in those with a family his-
tory of neural tube defects. Although phenobarbital
crosses the placenta and may cause foetal sedation and
neonatal withdrawal syndrome, it probably has the least
teratogenicity potential.6 In general, major congenital
malformations occur in 4% to 6% of children born
from epileptic mothers,14,16 which is similar to the
results of this review (6.86%) [Table 2].
 The principles of management are as follows6,21,22:
(1) female epileptic patients of reproductive age should
be educated on the risks associated with pregnancy;
(2) the diagnosis of epilepsy should be definite, and
the need for continued antiepileptic therapy should be
evaluated before conception occurs; (3) mono-therapy
is preferred, the least number of drugs at the lowest
effective dose should be used, and new anti-epileptic
medications should be avoided. After conception,
adjustments in medication offer no benefit but may
increase the risk of seizure; (4) the pre-conceptional
use of multivitamins and folate is beneficial. During
pregnancy, attention should be directed to factors that
reduce seizure control and the monitoring of anticon-
vulsant levels is needed. Free drug levels are preferred
in difficult cases; and (5) following delivery, dosage
adjustment is needed especially in lactating mothers.
The assessment of infants and children of epileptic
mothers for long-term complications and developmen-
tal delay is advisable.
Eclampsia
Pre-eclampsia or toxaemia gravidarum is a complex
disorder with pregnancy-induced hypertension, pro-
teinuria, and oedema developing after 20 weeks of
gestation. Eclampsia, a life-threatening complication
of gestational hypertension with high maternal and
perinatal mortality, is diagnosed when seizure or
coma occurs in a pre-eclamptic patient.23 Eclamptic
seizures, which may be focal motor or generalised
tonic-clonic, usually appear within the first 24 hours
postpartum. The underlying causes for pre-eclampsia
and eclampsia remain unknown, but abnormal immu-
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nological interactions between foetal and maternal
tissues are involved.24 The neuropathological changes
in eclampsia include diffuse cerebral oedema, sub-
arachnoid haemorrhage, subcortical haemorrhage,
small haemorrhages, and microinfarctions at several
levels of the neuraxis.23 Many eclamptic patients have
visual symptoms secondary to pathophysiological
changes in the eye or visual cortex, and cerebral va-
sospasm may be responsible.25 Metabolic or hyper-
tensive encephalopathy may also contribute to the
pathogenesis of eclampsia.
In severe pre-eclampsia and eclampsia, immediate
delivery of a viable baby and maintenance of maternal
health are the therapeutic goals.23 Thus, treatment
strategies include control of arterial blood pressure
within the range of cerebral autoregulation, reduction
of cerebral oedema, and rapid control and prevention
of seizures. Use of magnesium sulphate is popular in
pre-eclampsia and eclampsia, even though this salt has
no proven anticonvulsant effect. Ongoing seizures
should be aborted with intravenous diazepam, and
phenytoin or chlormethiazole may prevent recurrent
seizures. An intravenous loading dose of phenytoin at
20 mg/kg may be followed with daily maintenance.
Neurological referral is advisable for the management
of seizures and cerebrovascular events.
Cranial and peripheral neuropathies
Idiopathic facial nerve palsy or Bell’s palsy is common
at all ages. The annual incidence is 17 per 100000 in
women of reproductive age and 38 to 45 per 100 000
during pregnancy and the post-partum period.26,27 When
facial nerve palsy is associated with pregnancy, 75%
of the cases are seen in the third trimester and early
post-partum period,28 which is in accordance with
the present results. Bell’s palsy is rarely bilateral or
recurrent in non-pregnant patients, but recurrence dur-
ing successive pregnancies and bilateral facial nerve
palsy in pregnant women have been described. The
prognosis for recovery is excellent, and a 10-day course
of steroids at 40 mg to 60 mg daily is safe during
pregnancy.26
Lumbosacral radiculopathy or plexopathy and
femoral, tibial, lateral femoral cutaneous, obturator,
and peroneal neuropathies may occur during pregnancy
and delivery.27 Abdominal neuropathies, carpal
tunnel syndrome, neuralgic amyotrophy, and chronic
inflammatory demyelinating polyneuropathy are as-
sociated with pregnancy, whereas Guillain-Barré
syndrome occurs randomly, irrespective of pregnancy.
These neurological disorders were not seen in this
review. Diagnosis is based on clinical assessment plus
appropriate neuroelectrophysiological tests. The man-
agement varies according to the diagnosis.
Pituitary tumours
The most common type of pituitary tumour in women
of reproductive age is the prolactinoma, which typically
causes amenorrhoea, galactorrhoea, and infertility.29
Most prolactinomas are microadenomas confined
within the sella turcica, but occasionally they become
macroadenomas and compress the optic chiasma and
other neighbouring structures. Magnetic resonance
imaging (MRI) of the head is preferred to computed
tomography (CT) to visualise pituitary tumours. As
hyperprolactinaemia suppresses ovulation, pregnancy
is associated with prolactinomas that have responded
to ergoline drugs such as bromocriptine or pergolide.
Empirical data do not suggest any increased risk for
abortion or congenital malformations after using these
ergoline drugs during pregnancy.30 The common
practice is to stop these drugs when pregnancy is
confirmed in patients with microadenomas. Most
patients have an uneventful pregnancy while not tak-
ing any medication.31 Unfortunately, a few patients
have a recurrence of symptoms or new complaints
during their pregnancies. In fact, the normal pituitary
gland enlarges in pregnancy and hyperplasia of prol-
actin-secreting cells occurs.32 This latter group is rep-
resented in this report by eight of the 10 patients with
prolactinoma. Under these circumstances, ergoline
treatment should be continued with regular monitor-
ing of visual fields, visual acuity, and other neurologi-
cal signs during pregnancy. Surgical resection is
reserved for those with severe or progressive clinical
features despite adequate medical treatment having
been given.29 Our results overemphasise the need to
continue ergoline treatment during pregnancy because
patients who had a past history of prolactinoma but
did not require treatment during pregnancy were ex-
cluded. This exclusion was necessary because of the
inconsistent entry of such histories in the database.
Cerebrovascular disorders
Pregnancy increases the risk of a cerebrovascular
event.33,34 The risk of bleeding from arterial aneurysms
and arteriovenous malformations is increased during
pregnancy. Haemodynamic, haematological, and
cardiovascular changes of pregnancy are associated
with arterial and venous thrombosis, arterial embolism,
and intracerebral haemorrhage. As indicated above,
eclampsia carries an additional risk of cerebral infarc-
tions and haemorrhage.23 Subarachnoid haemorrhage
predominated in this study, and cerebral infarction
and cerebral venous thrombosis were not observed. In
general, a neurological consultation is indicated, CT
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or MRI of the head is needed, and appropriate man-
age-ment should be offered depending on the diagno-
sis and assessment.33,34
Non-traumatic subarachnoid haemorrhage is caused
by the rupture of berry aneurysms and arteriovenous
malformations in most cases.34 Rarely, haematological
disorders, bacterial endocarditis, and metastatic cho-
riocarcinoma are responsible. The risk of aneurysmal
bleeding increases with the duration of pregnancy and
so most haemorrhages occur in the third trimester;
re-bleeding is a risk during labour.34-36 In contrast,
arteriovenous malformations bleed more often during
the second trimester or during labour. Patients with
subarachnoid haemorrhage who are comatose on
presentation are likely to die, and patients surviving
an initial bleed may succumb to re-bleeding.34 Com-
puted tomography of the head or lumbar puncture is
diagnostic, and four-vessel cerebral angiography is
indicated.33 Nimodipine may be used despite a lack of
scientific data supporting its use in pregnant women.
Neurosurgical referral and definitive treatment of the
underlying cause are crucial. An elective caesarean
section is often used to deliver the baby near term.
Intracerebral haemorrhage is a rare but serious
disorder in pregnancy with an associated mortality rate
of 40% to 50%.37 The differential diagnoses are venous
infarction or haemorrhagic transformation of arterial
infarction. The causes are the same as in non-pregnant
patients, and include hypertension, arteriovenous
malformations, anticoagulation treatment, bleeding
disorders, and brain tumours. Management depends
on the underlying cause and size of the haematoma.
Both transient ischaemic attacks and ischaemic
stroke occur five to 10 times more commonly during
pregnancy and the puerperium than they do in non-
pregnant women of the same age.33,34 The risk is
probably highest in the first week post partum. Athero-
thrombosis, cardioembolism, artery-to-artery embo-
lism, hypercoagulability, haemodynamic disturbances,
and other rare causes are responsible. Specific treat-
ment should be offered to deal with any underlying
cause and associated stroke risk factors. Low-dose
aspirin is safe during pregnancy. Coumadin is terato-
genic and should be avoided before conception and
during the first trimester; heparin is the anti-coagulant
of choice during pregnancy despite being inconvenient.
Cerebral venous thrombosis is a rare type of stroke
associated with the puerperium33,34,38; the cause is
unknown in most cases. Magnetic resonance imaging
and angiography are the preferred diagnostic tests. The
clinical presentations depend on the site and severity
of the bleed, but headache, focal neurological signs,
and focal seizures are common. Anticoagulation for
2 to 3 months is the popular treatment despite the
absence of any supporting evidence.
Myasthenia gravis
Myasthenia gravis is a rare disorder with fluctuating
fatiguability of skeletal muscles and unpredictable
exacerbations and is occasionally seen in pregnancy
because this chronic disease is twice as common in
females and has a peak incidence in the reproductive
years.27 The neuromuscular block is caused by an
autoimmune mechanism, and anti–acetylcholine
receptor antibody is detectable in 90% of affected
patients.39 Antistriated muscle antibody is associated
with an underlying thymoma. In the pre-thymectomy
era, one third of myasthenic patients deteriorated
during their pregnancies, one third had their health
unchanged, and one third improved.27 In addition,
the disease course for any one pregnancy does not
predict the course during subsequent pregnancies.
Exacerbations are common in the first few weeks
post partum.
Thymectomy is indicated for thymoma and is rec-
ommended in all young myasthenic patients who have
a deteriorating response to an anticholinesterase drug.27,39
The thymoma should be resected prior to a planned
pregnancy; otherwise the tumour becomes more ag-
gressive or develops metastases during pregnancy.
Steroid-sparing immunosuppressants such as azathio-
prine should be discontinued prior to pregnancy ow-
ing to the risk of teratogenicity.27 Corticosteroid therapy
also poses a risk to both the mother and the foetus.
The oral or intramuscular administration of quarternary
ammonium compounds such as pyridostigmine and
neostigmine is safe as there is little passage through
the placenta. Magnesium sulphate, aminoglycosides,
and muscle relaxants may cause a myasthenic crisis
and should be avoided. Although myasthenia gravis can
present initially in pregnant patients and the control may
become poor during pregnancy, early termination of the
pregnancy is neither necessary nor beneficial.27 Aggres-
sive treatment with plasmapheresis throughout pregnancy
and thymectomy in the second trimester can result in
favourable outcomes.40 As the IgG type anti–acetylcho-
line receptor antibodies can cross the placenta, all
neonates born of myasthenic mothers should be evalu-
ated for transient symptoms and signs of neonatal
myasthenia and respiratory distress.27
Multiple sclerosis
Multiple sclerosis is a multifocal demyelinating dis-
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ease of the central nervous system characterised by
remissions and relapses, resulting in white-matter
lesions that are disseminated in space and time.29,41 The
incidence of multiple sclerosis is 8.8 per 100 000 in
the Hong Kong Chinese population42; this incidence is
low when compared with western populations or other
Asian populations.43 At onset, 65% of patients have a
relapsing/remitting course, 15% have relapsing/pro-
gressive disease, and 20% have a chronic progressive
form.41 The underlying cause remains unknown, but
immunological factors are involved.44 A short course
of steroids may shorten the acute relapse but this has
no effect on the relapse rate nor the prognosis. Other-
wise treatment is largely supportive; use of immuno-
suppressants is empirical.41,45-47 Recent data indicate
that long-term use of β-interferon can reduce the
clinical relapse rate and the disease activity as seen by
MRI.46,47
Multiple sclerosis does not affect fertility or the
course and outcome of pregnancy, labour, and
delivery.29,48 In addition, carefully designed studies have
failed to show that pregnancy can cause multiple
sclerosis or precipitate its onset. On the other hand,
the disease activity is modified during pregnancy. Most
studies report an antepartum decrease in disease
activity and an increase in relapse rates post partum.49
The latter also applies to myasthenia gravis and other
autoimmune diseases. Thus, the overall relapse rate
remains unchanged.29,48 If a relapse is encountered
during pregnancy, a course of corticosteroids may be
given. The safety of β-interferon during pregnancy has
not been established.
Non-pituitary intracranial tumour
Apart from pituitary tumours, all other types of intra-
cranial tumour have been reported during pregnancy.
Gliomas, meningiomas, and acoustic neuromas pre-
dominate in descending order of frequency, but only
choriocarcinomas are specifically associated with preg-
nancy.29 In general, intracranial tumours enlarge dur-
ing pregnancy owing to the associated physiological
changes, and regression may follow delivery. Receptors
for sex steroids are found in meningiomas, neurofi-
bromas, and some gliomas. Diagnosis is based on
the clinical features and the characteristic findings on
CT or MRI of the head. Management varies according
to the type of intracranial tumour.29 A neurosurgical
consulta-tion is indicated. Therapeutic or prophylac-
tic anti-epileptic medications are useful. Cortico-
steroids improve the vasogenic oedema. Regular moni-
toring of symptoms, signs, and tumour size is crucial
in planning treatment such as surgery, chemotherapy,
and radiotherapy.
Other neurological conditions
Other neurological conditions that may be seen dur-
ing pregnancy were not observed in our local obstetric
population during the period of review. Headaches
are extremely common in women, irrespective of
pregnancy.50 Common benign causes include migraine,
tension headache, and acute sinusitis. Symptomatic
headache occurs in subarachnoid haemorrhage,
intracerebral haemorrhage, cerebral venous throm-
bosis, benign intracranial hypertension, and intracranial
tumour.
Movement disorders occur infrequently during
pregnancy.51 Restless leg syndrome is the most com-
mon movement disorder and is characterised by a
crawling, burning, or aching sensation in the calves,
with an irresistible urge to move the legs. In general,
this syndrome presents during the second or third
trimester and resolves following delivery. Benzo-
diazepam, clonazepam, levodopa/carbidopa, and
codeine are often used to relieve symptoms. Chorea
gravidarum is not a distinct condition but refers to
chorea of any cause starting in pregnancy. Major causes
are Sydenham’s chorea, systemic lupus erythematosus,
and neuroleptic-induced chorea. Less common causes
include hyperthyroidism, Wilson’s disease, cerebro-
vascular disorders, and meningovascular syphilis.51
Many connective tissue disorders preferentially
affect young women of reproductive age.52 Although
neurological manifestations are seen in these disorders,
there is no increased frequency during pregnancy.
Management depends on the underlying diagnosis and
the neurological manifestation.
Conclusion
Many different neurological conditions may be encoun-
tered during pregnancy, whereas only eight types were
seen in our review of a local database. Epilepsy is the
most predominant condition. Effects of the condition
and its treatment on pregnancy and the effects of preg-
nancy on the condition and its treatment should be kept
in mind when dealing with these conditions in preg-
nancy. Appropriate manage-ment, preferably under the
joint care of obstetricians, neurologists, neurosurgeons,
and paediatricians in established centres, will ensure
successful foetal and maternal outcomes.
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